Advertisement

Topics

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

2014-09-18 14:21:07 | BioPortfolio

Published on BioPortfolio: 2014-09-18T14:21:07-0400

Clinical Trials [4165 Associated Clinical Trials listed on BioPortfolio]

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or ...

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body. Vorinostat may stop the growth of tumor cell...

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find o...

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and t...

Clinical Trial of SAHA in Patients With Breast Cancer

Purpose: - evaluate the safety of Vorinostat. - evaluate the effectiveness of Vorinostat in treating breast cancer - evaluate how the study subject's body reacts to Vorin...

PubMed Articles [22071 Associated PubMed Articles listed on BioPortfolio]

Prior exposure of pancreatic tumors to sorafenib + vorinostat enhances the efficacy of an anti-PD-1 antibody.

Checkpoint immunotherapy antibodies have not shown efficacy in pancreatic adenocarcinoma. Pre-clinical studies and subsequently an on-going phase I trial have demonstrated the safety and efficacy of c...

Effect of valproic acid in comparison with vorinostat on cell growth inhibition and apoptosis induction in the human colon cancer SW48 cells in vitro.

Acetylation levels of histones are the result of the balance between histone acetyltransfrases and histone deacetylases activities, which plays an important role in chromatin remodeling and regulation...

Cognitive Function and Quality of Life in Vorinostat-Treated Patients Following Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplant.

Myeloablative conditioning allogeneic hematopoietic cell transplantation (HCT) puts patients at greater risk for significant cognitive and quality of life decline compared with recipients of reduced i...

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.

Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments. Being able to do this ...

Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy.

To optimize the synergistic efficacy of combination therapy with controlled molar ratio, complex small molecule-based nanodrug (Co-SMND) of 5-fluorouracil (5-Fu)/vorinostat (SAHA) was developed.

Medical and Biotech [MESH] Definitions

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

More From BioPortfolio on "A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial